Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
RESEARCH TOOLSreports
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
<0.01Last Year’s EPS
0.1Same Quarter Last Year
Moderate Buy
Based on 15 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: -4.42%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial results, pipeline expansion, and global growth plans, but also acknowledged challenges in revenue guidance due to pricing and regulatory uncertainties. Despite these hurdles, the company remains optimistic about its future growth and strategic initiatives.Company Guidance
During the ACADIA Pharmaceuticals conference call, leadership provided a comprehensive overview of the company's fiscal performance for 2024 and guidance for 2025. The company reported total revenues of $957.8 million in 2024, reflecting a 32% increase year-over-year, with DAYBUE and NUPLAZID contributing $348.4 million and $609.4 million, respectively. DAYBUE achieved a 97% increase in sales compared to 2023, while NUPLAZID saw an 11% increase. ACADIA projected 2025 total revenues to range from $1.03 billion to $1.095 billion, with DAYBUE expected to generate $380 million to $405 million in U.S. net sales and NUPLAZID anticipated to bring in $650 million to $690 million. The company highlighted a 15% quarter-over-quarter improvement in DAYBUE patient discontinuations and a 13% year-over-year growth in NUPLAZID's fourth-quarter sales. ACADIA also discussed strategic initiatives to drive growth, including expanding commercial leadership and launching direct-to-consumer campaigns. Additionally, the company outlined plans for international expansion, with EMA approval for trofinetide anticipated in the first quarter of 2026, and emphasized the depth and potential of its pipeline across neuroscience and neuro rare diseases.Strong Financial Performance
Record quarterly revenues with DAYBUE sales reaching $96.7 million in Q4, up 11% year-over-year, and full-year sales at $348.4 million, up 97% from 2023. NUPLAZID sales hit $162.9 million in Q4, up 13% year-over-year, with full-year sales at $609.4 million, up 11%.
Pipeline Expansion
Introduction of ACP-711 for essential tremor and the addition of a second indication for ACP-204 in Lewy Body Dementia Psychosis. A broader pipeline with programs spanning neuroscience and rare diseases was disclosed.
Global Expansion Plans
Submission of a marketing application with the European Medicines Agency for trofinetide, anticipating EMA approval in Q1 2026. First DAYBUE sales in Canada expected in Q3 2025 and plans for managed access programs in Europe.
Financial Guidance for 2025
Total revenues expected to be in the range of $1.03 billion to $1.095 billion. DAYBUE U.S. net sales are projected to be between $380 million and $405 million, while NUPLAZID sales are expected to range from $650 million to $690 million.
Strong Cash Position
Ending 2024 with a cash balance of $756 million, up from $438.9 million at the end of 2023, primarily driven by cash flows from operations and the sale of a priority review voucher.
---
ACAD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ACAD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $19.00 | $19.34 | +1.79% |
| Nov 06, 2024 | $15.79 | $17.20 | +8.93% |
| Aug 06, 2024 | $18.85 | $15.17 | -19.52% |
| May 08, 2024 | $17.13 | $15.21 | -11.21% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does ACADIA Pharmaceuticals (ACAD) report earnings?
ACADIA Pharmaceuticals (ACAD) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is ACADIA Pharmaceuticals (ACAD) earnings time?
ACADIA Pharmaceuticals (ACAD) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ACAD EPS forecast?
ACAD EPS forecast for the fiscal quarter 2025 (Q1) is <0.01.
---